Futuximab

Names

[ Name ]:
Futuximab

Biological Activity

[Description]:

Futuximab is a chimeric monoclonal antibody targeting non-overlapping epitopes on EGFR. Futuximab has antineoplastic activity[1].

[Related Catalog]:

Research Areas >> Cancer

Signaling Pathways >> JAK/STAT Signaling >> EGFR

Signaling Pathways >> Protein Tyrosine Kinase/RTK >> EGFR

[In Vitro]

Futuximab (20 µg/mL; 24-48 h) induces EGFR variant III (EGFRvIII) internalization and slightly reduces EGFRvIII levels in NR6M cells[1]. Western Blot Analysis[1] Cell Line: NR6M cells Concentration: 20 µg/mL Incubation Time: 24 h or 48 h Result: Slightly reduced EGFRvIII levels in NR6M cells.

[In Vivo]

Futuximab (50 mg/kg; i.p.; twice weekly; for 5 weeks) shows anti-tumor activity in EGFRwt expressing xenograft model[1]. Animal Model: Balb/c nu/nu mice injected with EGFRwt (D08-0308MG) patient-derived glioblastoma xenografts (PDX)[1] Dosage: 50 mg/kg Administration: i.p.; twice weekly; for 5 weeks Result: Inhibited tumor growth in EGFRwt expressing xenograft model.

[References]

[1]. Stephen T Keir, et al. Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models. J Neurooncol. 2018 Jul;138(3):489-498.

Chemical & Physical Properties

No Any Chemical & Physical Properties

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.